Syndax Sees Subgroup Efficacy For Entinostat Plus Keytruda In NSCLC

The company says a subgroup of lung cancer patients with high pre-treatment monocyte levels showed promising response and PFS rates in study pairing Syndax’s selective HDAC inhibitor with Merck’s Keytruda. Mature data will inform future Phase III melanoma plans.